Stay updated on CC-486 and Venetoclax for AML Clinical Trial
Sign up to get notified when there's something new on the CC-486 and Venetoclax for AML Clinical Trial page.

Latest updates to the CC-486 and Venetoclax for AML Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe record history includes a new revision entry (v3.4.2) and the prior government funding/operating-status notice has been removed. The rest of the page content and structure remains unchanged.SummaryDifference0.8%

- Check25 days agoChange DetectedAdded a site-wide government funding notice and updated the system version to v3.4.1; removed the prior version v3.4.0 from the history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check32 days agoChange DetectedRecord History now includes a glossary toggle, color-coded change highlights (green for additions and red for deletions), and an updated revision label (v3.4.0) with related footer text. These updates are formatting and labeling enhancements rather than substantive changes to the trial data.SummaryDifference1%

- Check39 days agoChange DetectedAdded new sections for Contacts/Locations, Eligibility, Outcome Measures, Oversight, and Study Status with updates on 2026-01-13 and 2026-01-15; deleted an entry from 2025-01-03.SummaryDifference0.9%

- Check46 days agoChange DetectedThe record history now shows an added Revision: v3.3.4 and removal of Revision: v3.3.3. This is a minor log update to the page's revisions; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check68 days agoChange DetectedAdded Revision: v3.3.3 to the Study Record Versions and removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the page footer.SummaryDifference0.2%

Stay in the know with updates to CC-486 and Venetoclax for AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CC-486 and Venetoclax for AML Clinical Trial page.